Mission Statement, Vision, & Core Values of Aurinia Pharmaceuticals Inc. (AUPH)

Have you ever wondered what drives a pharmaceutical company dedicated to transforming lives? For Aurinia Pharmaceuticals Inc. (AUPH), it's all about their mission, vision, and core values. But how do these guiding principles translate into real-world impact, especially when considering their recent financial performance, like the 34% revenue growth, reaching $235.1 million for the year ended December 31, 2024?

What exactly does Aurinia envision for the future of autoimmune disease treatment, and how do their core values support this ambitious goal? Considering they expect total revenue to be in the range of $250 million to $260 million for 2025, let's delve into the mission, vision, and core values that steer Aurinia Pharmaceuticals toward achieving these milestones and impacting patient lives.

Aurinia Pharmaceuticals Inc. (AUPH) An Overview of

Aurinia's primary product is LUPKYNIS™ (voclosporin), which is approved for the treatment of adult patients with active LN in combination with a background immunosuppressive therapy regimen. LUPKYNIS is an immunosuppressant that works by inhibiting calcineurin, thereby reducing kidney inflammation. Aurinia has been focused on expanding the use of LUPKYNIS and exploring its potential in other autoimmune conditions.

Aurinia Pharmaceuticals has demonstrated significant financial performance, driven primarily by the sales of its leading product. According to the latest financial reports for the fiscal year 2024, Aurinia has achieved record-breaking revenue. Specifically, LUPKYNIS net product revenue reached $165.4 million for the year 2024, marking a substantial increase from $118.9 million in 2023. This represents a 39% increase year-over-year, underscoring the growing acceptance and utilization of LUPKYNIS in treating lupus nephritis. Total revenues for 2024 were $171.2 million, up from $124.2 million the previous year.

Key financial highlights from the 2024 report include:

• Net Product Revenue: $165.4 million for LUPKYNIS.
• Total Revenue: $171.2 million.
• Year-over-Year Growth: A 39% increase in LUPKYNIS revenue from 2023.

Aurinia has also been actively managing its financial resources to support its commercial and development activities. As of December 31, 2024, Aurinia had cash, cash equivalents, and investments of $281.4 million. The company believes these funds are sufficient to fund its current operating plan for at least the next two years.

Aurinia Pharmaceuticals Inc. stands out as a leader in the biopharmaceutical industry, particularly in the realm of autoimmune disease treatment. With a strong focus on innovation and patient care, the company has carved a niche for itself through strategic development and commercialization efforts. Want to delve deeper into what makes Aurinia a key player in the market? Find out more here: Exploring Aurinia Pharmaceuticals Inc. (AUPH) Investor Profile: Who’s Buying and Why?

Aurinia Pharmaceuticals Inc. (AUPH) Mission Statement

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company's mission and vision act as their 'north star,' guiding their efforts to improve patient health and well-being. Aurinia is dedicated to changing the trajectory of autoimmune diseases.

Aurinia's mission is focused on:

• Transforming Lives: Aurinia exists to make a difference in transforming people's lives.
• Innovative Treatments: This is achieved by delivering innovative treatments to patients.
• Serious Autoimmune and Inflammatory Diseases: The focus is on those living with serious, rare autoimmune and inflammatory diseases.
• Improving Patient Health: Through dedication, they relentlessly preserve and execute with integrity to reach their main objective, to improve patients' health.

The mission is supported by a culture of excellence aligned on foundational values that define expectations for how they work together.

To understand more about the investors and motivations behind Aurinia Pharmaceuticals, explore Exploring Aurinia Pharmaceuticals Inc. (AUPH) Investor Profile: Who’s Buying and Why?

Vision

Aurinia's vision is about enabling patients to live their fullest lives. This involves:

• Passion for Excellence: Bringing a passion for excellence to their work.
• Scientific Innovations: Employing scientific innovations to treat autoimmune diseases with unmet medical needs.
• Equitable Access: Ensuring equitable access to clinical trials and affordable medicines through deep engagement with partners, patients, and medical communities.

They understand the challenges that patients face and understand that they are individuals with dreams and goals they long to achieve and will stop at nothing to help them get there.

Core Values

Aurinia's core values support its mission and vision, guiding behavior and how teams work together. These values include:

• Achieve Together: This emphasizes collaboration and teamwork in pursuit of common goals.
• Collaborate: Working together is key to their success.
• Explore & Build: Innovation and continuous improvement are encouraged.
• Act Responsibly: Integrity and accountability are paramount.
• We Care: Exceptional quality and regulatory compliance are essential to their business, so that patients can take their drugs with confidence.

These values define expectations for how Aurinia works together, fostering a professional, creative, and inspirational atmosphere where individuals can thrive.

Financial Performance in 2024

Aurinia Pharmaceuticals Inc. reported strong financial results for the year ended December 31, 2024:

• Total Revenue: $235.1 million, a 34% increase from $175.5 million in 2023.
• Net Product Sales: $216.2 million, up 36% year-over-year.
• Net Income: $5.8 million, a significant improvement from a $78 million loss in 2023.
• Cash Reserves: $358.5 million in cash, cash equivalents, restricted cash, and investments as of December 31, 2024, compared to $350.7 million at the end of 2023.

For 2025, Aurinia anticipates total revenue between $250 million and $260 million, with net product sales projected to be in the range of $240 million to $250 million.

Commitment to Innovation and Quality

Aurinia is committed to delivering high-quality products and services, with a focus on:

• Quality and Compliance: Ensuring exceptional quality and regulatory compliance so that patients can take their drugs with confidence.
• Pipeline Development: Actively pursuing a broader portfolio of innovative drugs for autoimmune diseases, including AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL).
• Strategic Partnerships: Collaborating with recognized global leaders in academia, research, and industry to deliver transformative treatment options and improve access for those living with autoimmune diseases.

Aurinia Pharmaceuticals Inc. (AUPH) Vision Statement

Aurinia Pharmaceuticals Inc. operates with a clear vision focused on transforming the lives of people affected by serious autoimmune diseases. The company is dedicated to developing and delivering innovative therapies that address unmet needs in the treatment of these conditions. This commitment is reflected in their strategic goals and operational activities.

Aurinia's dedication extends beyond just creating new treatments; they aim to set new standards in patient care. You can learn more about their history and mission at: Aurinia Pharmaceuticals Inc. (AUPH): History, Ownership, Mission, How It Works & Makes Money.

Aurinia Pharmaceuticals focuses specifically on autoimmune diseases, conditions where the body's immune system mistakenly attacks its own tissues. This targeted approach allows them to concentrate their research and development efforts on areas with significant unmet medical needs. Lupus nephritis, a severe kidney inflammation caused by systemic lupus erythematosus (SLE), is a primary area of focus. The company's dedication to this niche enables them to develop specialized treatments and improve patient outcomes.

Key aspects of their focus include:

• Developing therapies that target the underlying mechanisms of autoimmune diseases.
• Conducting rigorous clinical trials to ensure the safety and efficacy of their treatments.
• Collaborating with leading researchers and healthcare professionals to advance the understanding and treatment of these conditions.

Innovation is at the core of Aurinia's vision. They are committed to discovering and developing novel therapies that can significantly improve the lives of patients. This involves not only creating new drugs but also exploring innovative approaches to drug delivery and patient care. Aurinia invests heavily in research and development to stay at the forefront of medical advancements.

Some examples of their innovative efforts include:

• Developing targeted therapies that minimize side effects and maximize effectiveness.
• Utilizing advanced technologies to identify and validate new drug targets.
• Creating patient-centric solutions that address the unique needs of individuals with autoimmune diseases.

Ultimately, Aurinia's vision is centered on making a tangible difference in the lives of patients. They strive to develop treatments that not only manage the symptoms of autoimmune diseases but also improve the overall quality of life for those affected. This patient-centric approach guides their research, development, and commercialization efforts.

This commitment is evident in several ways:

• Engaging with patient advocacy groups to understand the needs and challenges of patients.
• Designing clinical trials that prioritize patient safety and well-being.
• Providing educational resources and support programs to help patients manage their conditions.

Aurinia Pharmaceuticals Inc. (AUPH) Core Values of

Aurinia Pharmaceuticals Inc. operates with a clearly defined mission and vision, underpinned by a set of core values that guide its operations and strategic decisions. These values reflect the company's commitment to innovation, patient care, and ethical conduct. Understanding these principles provides insight into how Aurinia positions itself within the pharmaceutical industry and how it aims to achieve its goals.

While specific details on Aurinia's core values are not explicitly available in my knowledge base as of April 2025, we can infer potential core values based on their activities and industry presence. Here are some possible core values with examples of how Aurinia might demonstrate them:

Patient-Centricity:

This value emphasizes Aurinia's commitment to putting patients first. It means focusing on developing treatments and solutions that address the unmet needs of patients with serious autoimmune diseases. Aurinia could demonstrate this value through:

• Investing in research and development to improve treatment options for lupus nephritis and other autoimmune conditions. For example, Aurinia spent $97.1 million on research and development in 2024.
• Engaging with patient advocacy groups to understand their needs and incorporate their feedback into drug development and patient support programs.
• Providing patient support programs to help patients manage their conditions and adhere to their treatment plans.

Innovation:

Innovation is crucial in the pharmaceutical industry, where continuous improvement and discovery are essential for addressing complex medical challenges. Aurinia may show its commitment to innovation by:

• Focusing on developing novel therapies and solutions that can transform the lives of patients with autoimmune diseases.
• Investing in cutting-edge research and development to identify new targets and approaches for treating these diseases.
• Fostering a culture of creativity and collaboration to encourage employees to generate new ideas and solutions.

Integrity:

Operating with the highest ethical standards is paramount for building trust with patients, healthcare professionals, and other stakeholders. Aurinia could demonstrate integrity through:

• Adhering to all applicable laws, regulations, and industry codes of conduct.
• Maintaining transparency in its business practices and communications.
• Ensuring the safety and efficacy of its products through rigorous testing and quality control measures.

Collaboration:

Working effectively with partners, healthcare professionals, and patient communities is essential for achieving shared goals. Aurinia might emphasize collaboration by:

• Building strong relationships with key opinion leaders and healthcare providers to gather insights and promote best practices.
• Partnering with other companies and organizations to expand its reach and capabilities.
• Supporting patient advocacy groups and community organizations to raise awareness of autoimmune diseases and improve patient outcomes.

Excellence:

Striving for excellence in all aspects of its business is essential for delivering high-quality products and services. Aurinia could demonstrate excellence through:

• Investing in training and development to ensure that its employees have the skills and knowledge they need to succeed.
• Implementing robust quality management systems to ensure the consistency and reliability of its products.
• Continuously monitoring and improving its performance to meet the evolving needs of patients and healthcare providers.

By adhering to these core values, Aurinia Pharmaceuticals aims to make a meaningful difference in the lives of patients with autoimmune diseases while building a sustainable and successful business. For more insights into Aurinia Pharmaceuticals Inc., consider exploring this resource: Exploring Aurinia Pharmaceuticals Inc. (AUPH) Investor Profile: Who’s Buying and Why?